In Actavis, the Supreme Court ruled that a "large and unexplained" payment from brands to generics may be evidence of anticompetitive conduct. This panel will examine post-Actavis lower-court decisions that have shed contradictory views, probing issues such as expected litigation costs, expected profits from continued sales, and the value of contemporaneous business transactions.
Moderator:
Lisa A. Jose Fales, Venable LLP
Speakers:
C. Scott Hemphill, New York University School of Law
John H. Johnson, Edgeworth Economics LLC
Peter R. Kohn, Faruqi & Faruqi LLP
Markus H. Meier, Assistant Director, Bureau of Competition, Federal Trade Commission
Karen N. Walker, Kirkland & Ellis LLP
Visit the conference page for more information about this event.